Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences' solid growth expected to continue, says SeeThruEquity

Reseach house SeeThruEquity issued an upbeat note on Pressure Biosciences following its first quarter results.
Pressure Biosciences' solid growth expected to continue, says SeeThruEquity

Reseach house SeeThruEquity issued an upbeat note on Pressure Biosciences Inc (OTCMKTS:PBIO) following its first quarter results.

The medtech and life sciences group began 2017 with nice growth, with revenues up 8% at $551,357 year-on-year, it said.

Business was particularly strong in the company's products and services segment, which demonstrated 16% annual growth led by strong instrument sales, noted SeeThruEquity.

"On its call with investors, PBIO management stated that it expected sales growth throughout the year as it expands distribution and selling partnerships, including the recently announced partnership with EKG Sales Associates; the company also expects an increase in grant revenues later in the year," it added.

A CE mark for Barocycler...

The research group also said that the firm had achieved its CE marking for its Barocycler 2320EXTREME sample instrument system faster than originally expected.

"The CE Marking is a significant milestone as it allows the Barocycler to be sold in Europe," it said.

"The company has announced that it is pursuing an uplisting to the Nasdaq, with a goal of completing the process by the end of 2Q17.

"We expect this move will require a transaction that will bring in much needed capital, but also affect shares outstanding, in order to meet minimum share price and shareholder's equity thresholds for a national listing," it added.

Last week, Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss."

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
October 10 2017
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use